Sight Sciences publishes results from MIGS study in AJO

Sight Sciences announced the results as published in the American Journal of Ophthalmology, or AJO, International of the large scale, comparative real-world clinical outcomes study of patients treated by three minimally invasive glaucoma surgery, or MIGS, technologies. Using the American Academy of Ophthalmology IRIS Registry, this large-scale MIGS study evaluated long-term two-year post-surgical outcomes among patients with primary open-angle glaucoma, or POAG, treated with the three most commonly used FDA-approved/cleared ab interno MIGS devices in the U.S. combined with cataract surgery, as well as for cataract surgery alone. OMNI facilitates an implant-free, ab interno procedure that addresses the three primary areas of resistance in the conventional outflow pathway. OMNI technology has been cleared by the FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. At 24 months, high baseline IOP patients who received the outflow procedure using OMNI technology had: the greatest numerical reduction in IOP, and the greatest numerical reduction in medication use. At 24 months, low baseline IOP patients who received the outflow procedure using OMNI technology had: the greatest numerical reduction in IOP, and a statistically significantly greater mean medication use reduction compared to all other treatment groups.